Recent

% | $
Quotes you view appear here for quick access.

China Commercial Credit, Inc. Message Board

garysnoop1 5224 posts  |  Last Activity: 9 hours ago Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • PLYMOUTH MEETING, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3 million milestone payment from Roche to Inovio.

    This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.

    Dr. J. Joseph Kim, President and CEO, said, "We are pleased our partnership has achieved this initial clinical advance emanating from the collaborative efforts at Roche and Inovio. While this is primarily a safety study, we will also investigate our therapy's impact on antibody and T-cell responses, which will help advance the product into further trials. Recent developments have seen several successful drugs built on hepatitis C treatments. Hepatitis B has a prevalence nearly double that of hepatitis C and antiviral treatment can control but usually does not eliminate the virus. A successful immunotherapy for hepatitis B holds significant potential."

    About INO-1800 for Hepatitis B

    Inovio has reported preclinical data showing its hepatitis B immunotherapy (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate that the immunotherapy may have potential in the treatment of hepatitis B infection. In a preclinical study, researchers found hepatitis B-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells.

    Hepatitis B and Liver Cancer

    One of the major causes and risk factors for liver cancer is infection by hepatitis B. The virus is extremely infectious - 100 times more so than HIV - and 240 million people are chronically infected worldwide. Hepatitis B contributes to an estimated one million deaths worldwide each year. Liver cancer is the third most common cancer and the most deadly, killing most patients within five years of diagnosis. About 600,000 new cases arise each year.

    About Inovio Pharmaceuticals, Inc.

    Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.

    This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate

    Read more: http://www.nasdaq.com/press-release/inovio-pharmaceuticals-and-roche-initiate-clinical-trial-for-inovios-dna-immunotherapy-to-treat-20150421-00063#ixzz3XwpRJDKa

  • garysnoop1 garysnoop1 22 hours ago Flag

    He came over to the light..Welcome my son..

  • Reply to

    HUGE bet on INO to FAIL!

    by ino_about_whining Apr 20, 2015 2:39 PM
    garysnoop1 garysnoop1 23 hours ago Flag

    Don't worry, the way things are unfolding and your not short you can sleep tight...Your not short are you ??

    Sentiment: Strong Buy

  • Reply to

    The Chart seems to say and ritely so..That

    by garysnoop1 Apr 20, 2015 4:29 PM
    garysnoop1 garysnoop1 23 hours ago Flag

    That will more than do it..It seems that if one project becomes viable, All are destined given percentages of success.This is one exciting time in a exciting stock..

    Sentiment: Strong Buy

  • Reply to

    The Chart seems to say and ritely so..That

    by garysnoop1 Apr 20, 2015 4:29 PM
    garysnoop1 garysnoop1 Apr 20, 2015 5:03 PM Flag

    I'm saying "we need news"..Da ah !! and that is the magic bullet,now do you get it..Damn..

  • Reply to

    The Chart seems to say and ritely so..That

    by garysnoop1 Apr 20, 2015 4:29 PM
    garysnoop1 garysnoop1 Apr 20, 2015 4:46 PM Flag

    Don't let the facts get in the way of good cheerleading..

    Sentiment: Strong Buy

  • Reply to

    The Chart seems to say and ritely so..That

    by garysnoop1 Apr 20, 2015 4:29 PM
    garysnoop1 garysnoop1 Apr 20, 2015 4:38 PM Flag

    Shooting the messenger is prohibited on this board, what did you read as a negative..Facts?? I'm not knocking ino

    Sentiment: Strong Buy

  • We won't push thru the 10.50s
    gap of last Nov....10.32 is almost exactly the high of that gap before we ran down to the 9.50 resistance.After numerous attempts and couldn't break thru that resistance,we headed for 6.50,as the chart shows.So,now we bang the hell out of 10.50 again.To break the resistance we will need news to do that,not momentum, momentum got us back up NEWS will push us thru..

    Sentiment: Strong Buy

  • Reply to

    Based on Hillary's questionable past ...

    by clyde54 Apr 18, 2015 12:00 AM
    garysnoop1 garysnoop1 Apr 18, 2015 9:36 AM Flag

    I also go by..Burn me once,shame on you, burn me twice, shame on me..

  • It was good while it lasted..Still long,I can't figure out why? Maybe it's the old "sell on the news thing" and we are just getting to much good news...(kiddin' ,I need something to smile about)

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Apr 14, 2015 3:18 PM Flag

    If..they could think...they wouldn't be short..Now their's something to ponder..

    Sentiment: Strong Buy

  • Reply to

    Finally ...some recognition..read..

    by garysnoop1 Apr 14, 2015 2:30 PM
    garysnoop1 garysnoop1 Apr 14, 2015 2:32 PM Flag

    Calls up...better than good..

  • is having a standout day -- jumping 4.2% to trade at $10.29, and bringing its year-to-date lead to 12%. Option traders have responded, setting their sights on the drugmaker's calls.

    Getting into the data, INO calls are being exchanged at twice the usual intraday rate. By the numbers, there are 767 contracts on the tape, more than three times the 208 puts traded. Looking more closely, one group of speculators may be banking on the shares to extend their lead deeper into double-digit territory, buying to open the stock's May 10 call for a volume-weighted average price (VWAP) of $1.20. As such, breakeven on the transaction is $11.20 (strike plus VWAP) -- territory not explored since mid-November.

    Sentiment: Strong Buy

  • Reply to

    Shorts..Hold on tight to those ankles..The

    by garysnoop1 Apr 14, 2015 10:44 AM
    garysnoop1 garysnoop1 Apr 14, 2015 10:53 AM Flag

    Advice...Bow your head and cover...come over to the light..

  • PUSH is on !!..can you feel the love ??

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Apr 13, 2015 12:21 PM Flag

    Tell it to DARPA...shmuck..

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Apr 13, 2015 10:46 AM Flag

    That transpired in the last week or so...Hopefully we build a base here for the next big move. We tested the low 9.00s today and it held, that's' a good sign.The truth is in the rest of the day..gl to all.

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Apr 13, 2015 9:34 AM Flag

    The down morning was BS theatrics. plan and simple...they contradict their own headlines..

  • Inovio Pharmaceuticals Inc (NASDAQ:INO)’s shares dropped -1.81% to $9.78, during the last trading session on Friday, as Inovio Pharmaceuticals, declared that it was recognized with a prestigious industry award at the World Vaccine Congress being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the worldwide industry as judged by a panel of global biotech industry stakeholders.

    These positive results represent the first study and first report of T cell immune responses generated in cancer patients after treatment with an Inovio DNA immunotherapy. The magnitude and characteristics of these interim immune response data mirror immune responses formerly observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints.

    Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical corporation, develops active DNA immunotherapies and vaccines in combination with proprietary electro oration delivery devices to prevent and treat cancers and infectious diseases.

    Sentiment: Strong Buy

CCCR
2.980.00(0.00%)Sep 11 2:11 PMEDT